Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations

Emicizumab is a factor (F)VIIIa-mimicking bispecific antibody recognizing FIXa and FX molecules. In the phase 1/2 clinical studies, once-weekly subcutaneous administration of emicizumab has shown a favorable safety profile with encouraging efficacy in the patients with hemophilia A (PwHA) irrespecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yada, Koji, Nogami, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613000/
https://www.ncbi.nlm.nih.gov/pubmed/31308776
http://dx.doi.org/10.2147/JBM.S175952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613000/
https://www.ncbi.nlm.nih.gov/pubmed/31308776
http://dx.doi.org/10.2147/JBM.S175952

Ejemplares similares